Enzo Biochem, Inc.
ENZBOTCHealthcare
$0.70
$-0.00(-0.16%)
Market Cap$36587801
P/E Ratio—
52W High$1.19
52W Low$0.252
Enzo Biochem, Inc. (ENZB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ENZB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2025Report Date: Jun 16, 2025EPS Actual
-$0.04
Revenue
$0.01B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
Jun 16, 2025
After Market Close
ENZB reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2026 | Mar 16, 2026 | — | — | — | — | — | — |
| ◌ Q4 FY2025 | Dec 15, 2025 | — | — | — | — | — | — |
| — Q2 FY2025 | Jun 16, 2025 | — | -$0.04 | — | $0.01B | — | — |
| — Q1 FY2025 | Mar 17, 2025 | — | -$0.02 | — | $0.01B | — | — |
| — Q4 FY2024 | Dec 16, 2024 | — | -$0.05 | — | $0.01B | — | — |
| — Q4 FY2024 | Oct 29, 2024 | — | -$0.26 | — | $0.01B | — | — |
| — Q2 FY2024 | Jun 13, 2024 | — | -$0.03 | — | $0.01B | — | — |
| — Q1 FY2024 | Mar 13, 2024 | — | -$0.06 | — | $0.01B | — | — |
Q1 FY2026
Mar 16, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Dec 15, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Jun 16, 2025
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Mar 17, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2024
Dec 16, 2024
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2024
Oct 29, 2024
EPS Actual
-$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q2 FY2024
Jun 13, 2024
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2024
Mar 13, 2024
EPS Actual
-$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2025 | Jun 16, 2025 | — | $0.59 | $0.57 | -3.39% |
| — Q1 FY2025 | Mar 17, 2025 | — | $0.50 | $0.47 | -5.49% |
| — Q4 FY2024 | Dec 16, 2024 | — | $1.02 | $1.01 | -0.98% |
| — Q4 FY2024 | Oct 29, 2024 | — | $1.12 | $1.13 | +0.89% |
| — Q2 FY2024 | Jun 13, 2024 | — | $1.16 | $1.13 | -2.59% |
| — Q1 FY2024 | Mar 13, 2024 | — | $1.27 | $1.23 | -3.15% |
| — Q4 FY2023 | Dec 15, 2023 | — | $1.30 | $1.33 | +2.31% |
| — Q4 FY2023 | Oct 27, 2023 | — | $1.36 | $1.38 | +1.47% |
Q2 FY2025-3.39%
Report Date
Jun 16, 2025
EPS Beat/Miss
—
Price Before
$0.59
Price After
$0.57
Q1 FY2025-5.49%
Report Date
Mar 17, 2025
EPS Beat/Miss
—
Price Before
$0.50
Price After
$0.47
Q4 FY2024-0.98%
Report Date
Dec 16, 2024
EPS Beat/Miss
—
Price Before
$1.02
Price After
$1.01
Q4 FY2024+0.89%
Report Date
Oct 29, 2024
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.13
Q2 FY2024-2.59%
Report Date
Jun 13, 2024
EPS Beat/Miss
—
Price Before
$1.16
Price After
$1.13
Q1 FY2024-3.15%
Report Date
Mar 13, 2024
EPS Beat/Miss
—
Price Before
$1.27
Price After
$1.23
Q4 FY2023+2.31%
Report Date
Dec 15, 2023
EPS Beat/Miss
—
Price Before
$1.30
Price After
$1.33
Q4 FY2023+1.47%
Report Date
Oct 27, 2023
EPS Beat/Miss
—
Price Before
$1.36
Price After
$1.38
Beat Rate0 / 8 quarters
Largest Move-5.49% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ENZB ends December
Enzo Biochem, Inc. (ENZB) most recently reported earnings on June 16, 2025 for Q2 FY2025, posting EPS of $-0.04 (in line with the analyst consensus of —). The next ENZB earnings date is expected around September 1, 2026.
Each quarter, investors track ENZB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ENZB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ENZB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ENZB earnings · 4 questionsEnzo Biochem, Inc.'s next earnings report is expected around September 1, 2026. ENZB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ENZB historically reports after market close (AMC).
ENZB earnings datewhen is ENZB earningsENZB next earnings datewhen does ENZB report earningsENZB earnings calendar
▸ Source: FMP · Enzo Biochem, Inc. SEC filings · US GAAP · Enzo Biochem, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026